The inclusion of ivWatch in the Innovation Products pathway marks a strategic shift in how NHS Trusts address the risks associated with peripheral IV therapy. While conventional manual assessments often fail to catch early-stage fluid leakage, the system uses optical sensing and predictive algorithms to flag complications before they escalate into severe injuries. This expedited approval provides a direct procurement route for Trusts managing high-risk infusions, ranging from oncology treatments to emergency care.

Clinical adoption has been heavily influenced by Andrew Barton, a Nurse Consultant at Frimley Health NHS Foundation Trust. Following a two-year deployment in his units that resulted in zero extravasation injuries, Barton’s work earned the HSJ Patient Safety Pilot Program of the Year award. His trials demonstrated that the system identifies infiltration events with perfect sensitivity, consistently outperforming intermittent visual checks. Maya Aquino-Guerrero, a Patient Safety Champion at NHS Supply Chain, noted that such real-time monitoring empowers clinicians to intervene before complications become costly or irreversible. The initiative is now scaling for broader national implementation, with a structured rollout planned over the next 18 months to integrate the monitoring devices across acute and specialty care units.